Hormone Refractory Prostate Cancer - Pipeline Review, H2 2011

Global Markets Direct, November 2011, Pages: 179

Hormone Refractory Prostate Cancer - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Hormone Refractory Prostate Cancer - Pipeline Review, H2 2011', provides an overview of the Hormone Refractory Prostate Cancer therapeutic pipeline. This report provides information on the therapeutic development for Hormone Refractory Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hormone Refractory Prostate Cancer. 'Hormone Refractory Prostate Cancer - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hormone Refractory Prostate Cancer.
- A review of the Hormone Refractory Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hormone Refractory Prostate Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hormone Refractory Prostate Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hormone Refractory Prostate Cancer pipeline depth and focus of Hormone Refractory Prostate Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Hormone Refractory Prostate Cancer Therapeutic Products under Development, Key Players in Hormone Refractory Prostate Cancer Therapeutics, Hormone Refractory Prostate Cancer Pipeline Overview, Hormone Refractory Prostate Cancer Pipeline, Hormone Refractory Prostate Cancer Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hormone Refractory Prostate Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Hormone Refractory Prostate Cancer
Hormone Refractory Prostate Cancer Therapeutics under Development by Companies
Hormone Refractory Prostate Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Hormone Refractory Prostate Cancer Therapeutics - Products under Development by Companies
Hormone Refractory Prostate Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Hormone Refractory Prostate Cancer Therapeutics Development
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
Eli Lilly and Company
Nektar Therapeutics
Oxford BioMedica plc
YM BioSciences Inc.
Ambrilia Biopharma Inc.
Novartis AG
Aphios Corporation
Astellas Pharma Inc.
Eisai Co., Ltd.
Pfizer Inc.
Celgene Corporation
Oncogenex Pharmaceuticals, Inc.
Green Cross Corporation
Hybrigenics S.A.
Cadila Pharmaceuticals Ltd.
CureVac GmbH
Ascenta Therapeutics, Inc.
TSD Japan, Inc.
Aprea AB.
Aragon Pharmaceuticals, Inc.
Vakzine Projekt Management GmbH
CytoVac A/S
Hormone Refractory Prostate Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
Halaven - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OGX-011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OGX-427 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NKTR-105 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QTI571 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Inecalcitol + Taxotere - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APH-M109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Irofulven - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TroVax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ABI-008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TheraCIM + Mitoxantrone + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Goserelin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TSD-0014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MG1102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hormone Refractory Prostate Cancer Therapeutics – Drug Profile Updates
Hormone Refractory Prostate Cancer Therapeutics - Discontinued Products
Hormone Refractory Prostate Cancer - Featured News
Aug 30, 2011: Adamis Begins Phase I/IIa Clinical Prostate Study
Jun 06, 2011: Exelixis's Cabozantinib Phase II Data Demonstrate Encouraging Clinical Activity In Patients With Metastatic Castration-Resistant Prostate Cancer
Feb 28, 2011: Epeius Biotechnologies REXIN-G Gains Phase III Product Designation From FDA
Feb 07, 2011: Harbor BioSciences Wraps Up Phase I/IIa Prostate Cancer Study
Jan 10, 2011: Enzon Receives IND Approval To Begin Phase I Prostate Cancer Study With EZN-4176
Nov 19, 2010: ZIOPHARM Presents New Darinaparsin Preclinical Data At EORTC-NCI-AACR Meeting
Nov 02, 2010: Hybrigenics Develops New Oral Formulations Of Inecalcitol
Oct 04, 2010: CureVac Presents Data From Phase I/IIa Clinical Study With CV9103 In Hormone-Refractory Prostate Cancer
Oct 01, 2010: Sanofi-Aventis Reports Results Of Phase III TROPIC Study Showing Improved Survival With Jevtana Injection In Second-Line Advanced Prostate Cancer
Sep 20, 2010: Hybrigenics Announces Phase IIa Clinical Study Results Of Inecalcitol In Hormone-Refractory Prostate Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Hormone Refractory Prostate Cancer, H2 2011
Products under Development for Hormone Refractory Prostate Cancer – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Bristol-Myers Squibb Company, H2 2011
Boehringer Ingelheim GmbH, H2 2011
Eli Lilly and Company, H2 2011
Nektar Therapeutics, H2 2011
Oxford BioMedica plc, H2 2011
YM BioSciences Inc., H2 2011
Ambrilia Biopharma Inc., H2 2011
Novartis AG, H2 2011
Aphios Corporation, H2 2011
Astellas Pharma Inc., H2 2011
Eisai Co., Ltd., H2 2011
Pfizer Inc., H2 2011
Celgene Corporation, H2 2011
Oncogenex Pharmaceuticals, Inc., H2 2011
Green Cross Corporation, H2 2011
Hybrigenics S.A., H2 2011
Cadila Pharmaceuticals Ltd., H2 2011
CureVac GmbH, H2 2011
Ascenta Therapeutics, Inc., H2 2011
TSD Japan, Inc., H2 2011
Aprea AB., H2 2011
Aragon Pharmaceuticals, Inc., H2 2011
Vakzine Projekt Management GmbH, H2 2011
CytoVac A/S, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Hormone Refractory Prostate Cancer Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Hormone Refractory Prostate Cancer, H2 2011
Products under Development for Hormone Refractory Prostate Cancer – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Prostate Cancer - Pipeline Review, H2 2012
• Metastatic Prostate Cancer - Pipeline Review, H2 2012
• Male Cancer - Pipeline Review, H2 2012
• Growth Hormone Deficiency - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Metastatic Colorectal Cancer - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Bladder Cancer - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012